No effect of omega-3 polyunsaturated fatty acid supplementation on inflammatory markers in familial hypercholesterolemia: a randomized crossover trial

References

• Svendsen K, Krogh HW, Igland J, et al. 2.5-fold increased risk of recurrent acute myocardial infarction with familial hypercholesterolemia. Atherosclerosis. 2021;319:28–34.
   PubMed Web of Science ®Google Scholar
• Besseling J, Hovingh GK, Huijgen R, et al. Statins in familial hypercholesterolemia: consequences for coronary artery disease and All-Cause mortality. J Am Coll Cardiol. 2016;68(3):252–260.
   PubMed Web of Science ®Google Scholar
• Chiva-Blanch G, Padro T, Alonso R, et al. Liquid biopsy of extracellular microvesicles maps coronary calcification and atherosclerotic plaque in asymptomatic patients With familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2019;39(5):945–955.
   PubMed Web of Science ®Google Scholar
• Holven KB, Narverud I, Lindvig HW, et al. Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment. Atherosclerosis. 2014;233(2):561–567.
   PubMed Web of Science ®Google Scholar
• Hovland A, Narverud I, Lie Oyri LK, et al. Subjects with familial hypercholesterolemia have lower aortic valve area and higher levels of inflammatory biomarkers. J Clin Lipidol. 2021;15(1):134–141.
   PubMed Web of Science ®Google Scholar
• Barale C, Bonomo K, Frascaroli C, et al. Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: a 12-month follow-up. Nutr Metab Cardiovasc Dis. 2020;30(2):282–291.
   PubMed Web of Science ®Google Scholar
• Narverud I, Ueland T, Nenseter MS, et al. Children with familial hypercholesterolemia are characterized by an inflammatory imbalance between the tumor necrosis factor alpha system and interleukin-10. Atherosclerosis. 2011;214(1):163–168.
   PubMed Web of Science ®Google Scholar
• Charakida M, Tousoulis D, Skoumas I, et al. Inflammatory and thrombotic processes are associated with vascular dysfunction in children with familial hypercholesterolemia. Atherosclerosis. 2009;204(2):532–537.
   PubMed Web of Science ®Google Scholar
• Christensen JJ, Osnes LT, Halvorsen B, et al. Altered leukocyte distribution under hypercholesterolemia: a cross-sectional study in children with familial hypercholesterolemia. Atherosclerosis. 2017;256:67–74.
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045–2051.
   PubMed Web of Science ®Google Scholar
• Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12(3):204–212.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Devalaraja M, Baeres FMM, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet. 2021;397(10289):2060–2069.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Pradhan A, et al. Low-Dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752–762.
   PubMed Web of Science ®Google Scholar
• O'Donoghue ML, Glaser R, Cavender MA, et al. Effect of losmapimod on cardiovascular outcomes in patients hospitalized With acute myocardial infarction: a randomized clinical trial. JAMA. 2016;315(15):1591–1599.
   PubMed Web of Science ®Google Scholar
• Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. The Cochrane Database of Systematic Reviews. 2020;2020(3):CD003177.
   Google Scholar
• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
   PubMed Web of Science ®Google Scholar
• Adili R, Voigt EM, Bormann JL, et al. In vivo modeling of docosahexaenoic acid and eicosapentaenoic acid-mediated inhibition of both platelet function and accumulation in arterial thrombi. Platelets. 2019;30(2):271–279.
   PubMed Web of Science ®Google Scholar
• AbuMweis S, Jew S, Tayyem R, et al. Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: a meta-analysis of randomised placebo-control human clinical trials. J Hum Nutr Diet. 2018;31(1):67–84.
   PubMed Web of Science ®Google Scholar
• Li K, Huang T, Zheng J, et al. Effect of marine-derived n-3 polyunsaturated fatty acids on C-reactive protein, interleukin 6 and tumor necrosis factor alpha: a meta-analysis. PloS One. 2014;9(2):e88103.
   PubMed Web of Science ®Google Scholar
• Gao LG, Cao J, Mao QX, et al. Influence of omega-3 polyunsaturated fatty acid-supplementation on platelet aggregation in humans: a meta-analysis of randomized controlled trials. Atherosclerosis. 2013;226(2):328–334.
   PubMed Web of Science ®Google Scholar
• Pirich C, Gaszo A, Granegger S, et al. Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients. Thromb Res. 1999;96(3):219–227.
   PubMed Web of Science ®Google Scholar
• Hande LN, Thunhaug H, Enebakk T, et al. Addition of marine omega-3 fatty acids to statins in familial hypercholesterolemia does not affect in vivo or in vitro endothelial function. J Clin Lipidol. 2019;13(5):762–770.
   PubMed Web of Science ®Google Scholar
• Hande LN, Kjellmo C, Pettersen K, et al. Effect of N-3 polyunsaturated fatty acids on lipid composition in familial hypercholesterolemia: a randomized crossover trial. Biomedicines. 2022;10(8):1809.
   PubMed Web of Science ®Google Scholar
• Hayward CP, Harrison P, Cattaneo M, et al. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost. 2006;4(2):312–319.
   PubMed Web of Science ®Google Scholar
• Paniccia R, Priora R, Liotta AA, et al. Platelet function tests: a comparative review. Vasc Health Risk Manag. 2015;11:133–148.
   PubMed Web of Science ®Google Scholar
• Blazek M, Blaha M, Pecka M, et al. Primary hemostasis in patients treated with LDL-apheresis for severe familiar hypercholesterolemia: a prospective pilot trial using PFA-100 analysis to rationalize therapeutic LDL-apheresis procedure. Hematology. 2007;12(6):571–576.
   PubMed Web of Science ®Google Scholar
• Larson MK, Shearer GC, Ashmore JH, et al. Omega-3 fatty acids modulate collagen signaling in human platelets. Prostaglandins Leukot Essent Fatty Acids. 2011;84(3-4):93–98.
   PubMed Web of Science ®Google Scholar
• Yusof HM, Miles EA, Calder P. Influence of very long-chain n-3 fatty acids on plasma markers of inflammation in Middle-aged men. Prostaglandins Leukot Essent Fatty Acids. 2008;78(3):219–228.
   PubMed Web of Science ®Google Scholar
• Lee KW, Blann AD, Lip GY. Effects of omega-3 polyunsaturated fatty acids on plasma indices of thrombogenesis and inflammation in patients post-myocardial infarction. Thromb Res. 2006;118(3):305–312.
   PubMed Web of Science ®Google Scholar
• Yang Y, Lu N, Chen D, et al. Effects of n-3 PUFA supplementation on plasma soluble adhesion molecules: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2012;95(4):972–980.
   PubMed Web of Science ®Google Scholar
• Suades R, Padro T, Crespo J, et al. Liquid biopsy of extracellular microvesicles predicts future major ischemic events in genetically characterized familial hypercholesterolemia patients. Arterioscler Thromb Vasc Biol. 2019;39(6):1172–1181.
   PubMed Web of Science ®Google Scholar
• Henno LT, Storjord E, Christiansen D, et al. Effect of the anticoagulant, storage time and temperature of blood samples on the concentrations of 27 multiplex assayed cytokines - Consequences for defining reference values in healthy humans. Cytokine. 2017;97:86–95.
   PubMed Web of Science ®Google Scholar
• Rangel-Huerta OD, Aguilera CM, Mesa MD, et al. Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomakers: a systematic review of randomised clinical trials. Br J Nutr. 2012;107 Suppl 2(Suppl 2):S159–S170.
   PubMedGoogle Scholar
• Allaire J, Couture P, Leclerc M, et al. A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the comparing EPA to DHA (ComparED) study. Am J Clin Nutr. 2016;104(2):280–287.
   PubMed Web of Science ®Google Scholar
• Vors C, Allaire J, Mejia SB, et al. Comparing the effects of docosahexaenoic and eicosapentaenoic acids on inflammation markers using pairwise and network Meta-Analyses of randomized controlled trials. Adv Nutr. 2021;12(1):128–140.
   PubMed Web of Science ®Google Scholar
• Schwingshackl L, Christoph M, Hoffmann G. Effects of olive oil on markers of inflammation and endothelial function– a systematic review and meta-analysis. Nutrients. 2015;7(9):7651–7675.
   PubMed Web of Science ®Google Scholar
• Hovland A, Aagnes I, Brekke OL, et al. No evidence of impaired endothelial function or altered inflammatory state in patients with familial hypercholesterolemia treated with statins. J Clin Lipidol. 2010;4(4):288–292.
   PubMed Web of Science ®Google Scholar